Evaluating Biochemically Recurrent Prostate Cancer: Histologic Validation of 18F-DCFPyL PET/CT with Comparison to Multiparametric MRI.
暂无分享,去创建一个
Baris Turkbey | Esther Mena | Joanna H Shih | Liza Lindenberg | Elliot Levy | Peter L Choyke | Janet F Eary | Peter Pinto | Bradford J Wood | Venkatesh Krishnasamy | Stephanie A Harmon | P. Choyke | J. Eary | E. Levy | S. Harmon | P. Pinto | B. Wood | B. Turkbey | D. Citrin | J. Shih | R. Madan | W. Dahut | Y. McKinney | Sarah E Reese | I. Lim | E. Mena | F. Lin | Yolanda L McKinney | Ilhan Lim | R. Chang | Richard Chang | Frank Lin | Anita Ton | Philip Eclarinal | Deborah E Citrin | William Dahut | Ravi Madan | L. Lindenberg | V. Krishnasamy | P. Eclarinal | A. Ton | Anita T. Ton | Frank I. Lin
[1] P. Choyke,et al. Multiparametric magnetic resonance imaging-transrectal ultrasound fusion-assisted biopsy for the diagnosis of local recurrence after radical prostatectomy. , 2015, Urologic oncology.
[2] B. Turkbey,et al. Prostate MR Imaging for Posttreatment Evaluation and Recurrence. , 2017, Radiologic clinics of North America.
[3] Sten Nilsson,et al. Efficacy and safety of radium-223 dichloride in patients with castration-resistant prostate cancer and symptomatic bone metastases, with or without previous docetaxel use: a prespecified subgroup analysis from the randomised, double-blind, phase 3 ALSYMPCA trial. , 2014, The Lancet. Oncology.
[4] Michael P Fay,et al. Pearson's chi‐square test and rank correlation inferences for clustered data , 2017, Biometrics.
[5] M. Gleave,et al. Local recurrence of prostate cancer after radical prostatectomy is at risk to be missed in 68Ga-PSMA-11-PET of PET/CT and PET/MRI: comparison with mpMRI integrated in simultaneous PET/MRI , 2017, European Journal of Nuclear Medicine and Molecular Imaging.
[6] A. Sidana,et al. Multiparametric Magnetic Resonance Imaging for Active Surveillance of Prostate Cancer , 2017, Balkan medical journal.
[7] P. Albers,et al. Prospective comparison of whole-body MRI and 68Ga-PSMA PET/CT for the detection of biochemical recurrence of prostate cancer after radical prostatectomy , 2019, European Journal of Nuclear Medicine and Molecular Imaging.
[8] J. Chen,et al. Role of magnetic resonance imaging in the detection of local prostate cancer recurrence after external beam radiotherapy and radical prostatectomy. , 2013, Clinical oncology (Royal College of Radiologists (Great Britain)).
[9] Nikolaos Dikaios,et al. Multiparametric MRI for detection of radiorecurrent prostate cancer: added value of apparent diffusion coefficient maps and dynamic contrast-enhanced images , 2015, Prostate Cancer and Prostatic Disease.
[10] T. Holland-Letz,et al. Comparison of PSMA-ligand PET/CT and multiparametric MRI for the detection of recurrent prostate cancer in the pelvis , 2019, European Journal of Nuclear Medicine and Molecular Imaging.
[11] M. Pomper,et al. 2-(3-{1-Carboxy-5-[(6-[18F]Fluoro-Pyridine-3-Carbonyl)-Amino]-Pentyl}-Ureido)-Pentanedioic Acid, [18F]DCFPyL, a PSMA-Based PET Imaging Agent for Prostate Cancer , 2011, Clinical Cancer Research.
[12] I. Burger,et al. Clinical performance of 68Ga-PSMA-11 PET/MRI for the detection of recurrent prostate cancer following radical prostatectomy , 2017, European Journal of Nuclear Medicine and Molecular Imaging.
[13] A. Jemal,et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries , 2018, CA: a cancer journal for clinicians.
[14] M. Schwaiger,et al. Value of 68Ga-PSMA HBED-CC PET for the Assessment of Lymph Node Metastases in Prostate Cancer Patients with Biochemical Recurrence: Comparison with Histopathology After Salvage Lymphadenectomy , 2016, The Journal of Nuclear Medicine.
[15] G. Pond,et al. The Contribution of Multiparametric Pelvic and Whole-Body MRI to Interpretation of 18F-Fluoromethylcholine or 68Ga-HBED-CC PSMA-11 PET/CT in Patients with Biochemical Failure After Radical Prostatectomy , 2019, The Journal of Nuclear Medicine.
[16] P. Stricker,et al. Treatment Outcomes from 68Ga-PSMA PET/CT–Informed Salvage Radiation Treatment in Men with Rising PSA After Radical Prostatectomy: Prognostic Value of a Negative PSMA PET , 2017, The Journal of Nuclear Medicine.
[17] W. Wadsak,et al. 68Ga-PSMA 11 ligand PET imaging in patients with biochemical recurrence after radical prostatectomy – diagnostic performance and impact on therapeutic decision-making , 2017, European Journal of Nuclear Medicine and Molecular Imaging.
[18] Kirsten L. Greene,et al. Optimal MRI sequences for 68Ga-PSMA-11 PET/MRI in evaluation of biochemically recurrent prostate cancer , 2017, EJNMMI Research.
[19] P. Choyke,et al. Future Perspectives and Challenges of Prostate MR Imaging. , 2017, Radiologic clinics of North America.
[20] Esther Mena,et al. Initial Evaluation of [18F]DCFPyL for Prostate-Specific Membrane Antigen (PSMA)-Targeted PET Imaging of Prostate Cancer , 2015, Molecular Imaging and Biology.
[21] P. Choyke,et al. Multiparametric MRI for the detection of local recurrence of prostate cancer in the setting of biochemical recurrence after low dose rate brachytherapy. , 2018, Diagnostic and interventional radiology.
[22] D. Johnston,et al. Analysis of clinicopathologic factors predicting outcome after radical prostatectomy , 2001, Cancer.